Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting BCL-XL in fibrolamellar hepatocellular carcinoma.
Shebl B, Ng D, Lalazar G, Rosemore C, Finkelstein TM, Migler RD, Zheng G, Zhang P, Jiang CS, Qureshi A, Vaughan R, Yarchoan M, de Jong YP, Rice CM, Coffino P, Ortiz MV, Zhou D, Simon SM. Shebl B, et al. Among authors: ortiz mv. JCI Insight. 2022 Sep 8;7(17):e161820. doi: 10.1172/jci.insight.161820. JCI Insight. 2022. PMID: 36073545 Free PMC article.
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.
Ortiz MV, Ahmed S, Burns M, Henssen AG, Hollmann TJ, MacArthur I, Gunasekera S, Gaewsky L, Bradwin G, Ryan J, Letai A, He Y, Naranjo A, Chi YY, LaQuaglia M, Heaton T, Cifani P, Dome JS, Gadd S, Perlman E, Mullen E, Steen H, Kentsis A. Ortiz MV, et al. JCI Insight. 2019 Aug 8;4(15):e127098. doi: 10.1172/jci.insight.127098. eCollection 2019 Aug 8. JCI Insight. 2019. PMID: 31391345 Free PMC article.
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening.
Lalazar G, Requena D, Ramos-Espiritu L, Ng D, Bhola PD, de Jong YP, Wang R, Narayan NJC, Shebl B, Levin S, Michailidis E, Kabbani M, Vercauteren KOA, Hurley AM, Farber BA, Hammond WJ, Saltsman JA 3rd, Weinberg EM, Glickman JF, Lyons BA, Ellison J, Schadde E, Hertl M, Leiting JL, Truty MJ, Smoot RL, Tierney F, Kato T, Wendel HG, LaQuaglia MP, Rice CM, Letai A, Coffino P, Torbenson MS, Ortiz MV, Simon SM. Lalazar G, et al. Among authors: ortiz mv. Cancer Discov. 2021 Oct;11(10):2544-2563. doi: 10.1158/2159-8290.CD-20-0872. Epub 2021 Jun 14. Cancer Discov. 2021. PMID: 34127480 Free PMC article.
Skin adnexal carcinoma with BRD3-NUTM2B fusion.
Rubio Gonzalez B, Ortiz MV, Ross DS, Busam KJ. Rubio Gonzalez B, et al. Among authors: ortiz mv. J Cutan Pathol. 2021 Dec;48(12):1508-1513. doi: 10.1111/cup.14107. Epub 2021 Aug 3. J Cutan Pathol. 2021. PMID: 34296453 Free PMC article.
Identification of a TP53 Deletion in an Undifferentiated Embryonal Sarcoma of the Liver Provides Clinically Relevant Longitudinal Detection of Circulating Tumor DNA.
Kothari P, Sauerhaft T, Bouvier N, Rodriguez-Sanchez MI, Shia J, Price A, Morjaria S, Gerstle JT, Shukla NN, Ortiz MV. Kothari P, et al. Among authors: ortiz mv. JCO Precis Oncol. 2021 Sep 7;5:PO.21.00102. doi: 10.1200/PO.21.00102. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34527851 Free PMC article. No abstract available.
Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.
Woods AD, Berlow NE, Ortiz MV, Dela Cruz F, Siddiquee A, Coutinho DF, Purohit R, Freier KET, Michalek JE, Lathara M, Matlock K, Srivivasa G, Royer-Pokora B, Veselska R, Kung AL, Keller C. Woods AD, et al. Among authors: ortiz mv. Pediatr Blood Cancer. 2022 Feb;69(2):e29401. doi: 10.1002/pbc.29401. Epub 2021 Oct 24. Pediatr Blood Cancer. 2022. PMID: 34693628 Free PMC article.
55 results